Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
212
resultados
Última actualización
30/07/2025 [06:52:00]
Resultados 25 a 50 de 212
Resumen de: CN120360969A
本发明公开了双靶向巨噬细胞膜纳米系统及其制备方法与应用，属于生物医药领域，MKA由AuNPs与线粒体靶向肽KLA连接后包裹于巨噬细胞膜内。制备时先合成AuNPs并修饰，再用巨噬细胞膜包裹。在治疗中，它能双靶向肿瘤细胞和线粒体，增强辐射诱导的DNA损伤，抑制DDR，激活免疫通路，促进T细胞浸润，还可消耗谷胱甘肽、放大氧化应激来增强免疫效果，与8GyX射线协同的剂量增强比达3.1。此外，MKA在体内生物相容性良好，血液循环时间长、肿瘤靶向性高且能快速经肾脏清除。该发明为肿瘤放射免疫治疗提供新途径，有助于推动临床肿瘤治疗的进步。
Resumen de: CN120360965A
本发明公开了一种基于多酚氧化偶联自组装的pH响应性口服纳米药物及其制备方法和应用。该纳米药物设计简单高效，本发明所述的纳米药物是基于多酚在酸性介质中通过氧化剂介导的氧化偶联自组装，提供了一种耐酸不耐碱的pH响应性口服递送载体。通过溶剂转换介导的解组装‑重组装作用，高效负载疏水性药物，制备得到口服纳米药物。本纳米策略极大的提高了疏水性药物的载药率，载药量高达50％。同时避免了纳米药物被恶劣的胃生理环境破坏，靶向肠道递送。基于生物活性的多酚载体与药物之间的双重抗炎抗氧化作用，该口服纳米药物能够作为优异的多功能药物制剂通过协同作用预防或治疗炎症性肠病。
Resumen de: CN120360189A
本发明公开了一种幼鹅养殖饲料，属于养殖饲料技术领域，来解决现有改进型饲料仍存在配方复杂、成本高、效果不稳定的问题，能量原料占55‑68%，优选62%；蛋白原料占22‑30%，优选26%；预混料占5‑8%，优选6.5%；功能添加剂占3‑7%，优选5.5%，通过复合酶制剂与微生态制剂的协同作用，显著提高了粗蛋白消化率，使其提升至78.6%（P＜0.01），有效提高了饲料的利用效率，利用纳米包被技术形成的缓释体系，使维生素D3半衰期延长至48小时，持续为幼鹅提供稳定的维生素D3来源，促进钙、磷吸收和骨骼发育，根据幼鹅不同生长阶段对钙、磷的需求，将钙磷比在1.8:1‑2.2:1进行梯度调整，满足幼鹅骨骼发育和新陈代谢的需求，减少因钙磷失衡导致的疾病。
Resumen de: US2025230471A1
The present disclosure provides compositions and methods for inserting heterologous payload sequences into a target-site in a host cell genome. The compositions and methods use non-LTR retrotransposon reverse transcriptase proteins that bind template RNAs comprising a payload sequence that encodes a protein or regulatory RNA. The template RNA can comprise modified uridines that are not cleavable by a ribozyme. The incorporation of modified uridines increases the efficiency of integration and expression of the payload sequence and decreases cellular toxicity.
Resumen de: US2025235524A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.
Resumen de: WO2025152109A1
A nano abiraterone acetate composition, a preparation method therefor, and an oral tablet thereof. The composition comprises abiraterone acetate, a suspending aid, a surfactant, and a stabilizer in percentage by weight of 1:(0.1-4):(6-20):(0.01-0.1), and is prepared by wet grinding, drying, and dewatering. The oral bioavailability of the product is improved by adding a cholate absorption-promoting agent, such that the influence of food on drug absorption is reduced.
Resumen de: US2025236645A1
This present disclosure provides RNA expression systems based on sequences from plant viruses, insect viruses, and flaviviruses that eliminate the need for expensive modifications. Methods to express and package an RNA polynucleotide without the need for in vitro transcription and lipid nanoparticles are provided. Also provided are methods to package an RNA polynucleotide using synthetic polyanhydride nanoparticles that are stable at room temperature and suitable for delivery by nasal spray.
Resumen de: US2025236599A1
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula I and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.
Resumen de: US2025235500A1
Disclosed in the present invention are a new polypeptide for promoting tissue repair, and the use thereof. The new polypeptide can promote the proliferation of human immortalized epidermal cells and the migration of human epidermal fibroblasts at a relatively low concentration, can promote the repair of wounds and ulcers, improves the aesthetic feeling of the skin, has low toxic side effects, has good application prospects, and can be used for preparing a drug and a medical instrument for treating wound surfaces, scalds and ulcers or for preparing an everyday chemical for improving the aesthetic feeling of the skin.
Resumen de: US2025235411A1
The present disclosure provides lipid nanoparticle compositions and methods of use. Among other things the present disclosure provides lipid nanoparticle compositions which increased specificity for specific cells or tissues. The present disclosure provides methods of use of the disclosed lipid nanoparticles.
Resumen de: US2025235404A1
Disclosed herein are polyethylene glycol (PEG)-lipids, functionalized PEG-lipids, and functionalized PEG-lipids that are conjugated to a binding moiety which can comprise an antibody antigen binding domain. Also disclosed are methods for synthesizing and functionalizing the PEG-lipids. The PEG-lipids are useful components lipid nanoparticles (LNP) used for the delivery of nucleic acids into living cells, in vivo or ex vivo. LNP comprising functionalized PEG-lipids that are conjugated to a binding moiety are useful as targeted LNP for delivering nucleic acids into cells or tissues expressing the ligand of the binding moiety.
Resumen de: US2025235394A1
Nanoparticles for treating a tooth in an oral cavity of a subject are provided. The nanoparticle comprises a biocompatible and biodegradable hydrophilic polymer, a matrix-degrading enzyme, and an anticaries active ingredient present in the nanoparticle at greater than or equal to about 20% by weight. The nanoparticle has a zeta potential between about −10 mV to about +10 mV at a pH of 7. The nanoparticle is capable of selectively accumulating within a biofilm matrix associated with a surface of the tooth in the oral cavity of the subject. Oral care composition and methods of treating a tooth in an oral cavity of a subject with such nanoparticles are also provided.
Resumen de: US2025235405A1
A nanoparticulate composition comprising a core comprising a therapeutically active agent selected from a nucleic acid, protein or peptide packaged within a non-viral drug delivery vehicle is described. The core comprises a low molecular weight stabilizing agent comprising at least one atom or group that is charged in aqueous solution, wherein when the therapeutic agent is negatively charged the charged atom or group is positively charged in aqueous solution and when the therapeutic agent is positively charged the charged atom or group is negatively charged in aqueous solution.
Resumen de: US2025235400A1
The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about −10 mV. Further provided are processes for preparing such nanoemulsions.
Resumen de: US2025235412A1
A poly(beta-aminoester) polymer of formula (I) or a pharmaceutically salt thereof which comprises one or more zwitterionic polymers. Advantageously, the polymer of the invention shows improved properties when formulated in the form of nanoparticles. Processes for the preparation of the polymer, nanoparticles comprising a polymer of Formula (I) and uses thereof.
Resumen de: US2025235401A1
An oil in water nanoemulsion has an oil phase and an aqueous phase and comprises active pharmaceutical ingredient (API), edible oil, denatured plant protein, surfactant, and water, in which the API is contained in the oil phase. The API comprises an RNA molecule or a hydrophobic drug. The oil is high oleic oil. The oil in water nanoemulsion may be combined with a suspension of denatured plant protein and a calcium salt chelating agent to form microparticles or microcapsules comprising the nanoemulsion or the oil droplets of the nanoemulsion encapsulated within a denatured plant protein matrix. The microcapsules can be ingested orally and pass through the stomach to the ileum where the protein matrix breaks down to release the oil droplets containing the API, which is then absorbed.
Resumen de: US2025235403A1
Disclosed herein are pH-sensitive nanoemulsions as well as methods of using thereof. These pH-sensitive nanoemulsions can comprise a lipid particle encapsulating an active agent. The lipid particle can comprise one or more ionizable lipids; one or more neutral lipids; one or more PEGylated lipids; and optionally one or more fusogenic oils. In some embodiments, these compositions can be buffered at an acidic pH (e.g., a pH of less than 6.5, such as a pH of from 4 to 6.5, or a pH of from 5.0 to 6.5). By buffering at an acidic pH, the delivery efficiency of the compositions can be enhanced as compared to otherwise identical compositions buffered at a pH of 7 or more.
Resumen de: US2025235402A1
An aqueous, intra-oral, nanoemulsion blend is provided that enhances mitochondrial performance in mammals when orally administered. The blend includes at least two different monolayer surfactant bound particle components and at least one bilayer water-core liposome component. The blend optionally may include a micelle.
Resumen de: US2025235537A1
Methods for targeted therapy are disclosed. In certain embodiments, a method includes injecting nanoparticles into a target site in or adjacent to an eye, irradiating the target site with light from a light source, and activating the nanoparticles with the light.
Resumen de: US2025235532A1
The present invention relates to a polymer-lipid hybrid nanoparticle comprising a lipid and a block copolymer, wherein the amount of said lipid, expressed in mole percentage (mole %) present in the polymer-lipid hybrid nanoparticle, wherein the mole percentage refers to the total amount of all components that form the polymer-lipid nanoparticle, is greater than the amount of said block copolymer, expressed in mole percentage, present in the polymer-lipid hybrid nanoparticle. The invention also relates to such a polymer-lipid hybrid nanoparticle further comprising a soluble encapsulated antigen, wherein said soluble encapsulated antigen is a protein and/or polynucleotide. The invention further relates to a method of encapsulating such an antigen in such a polymer-lipid hybrid nanoparticle as well as to a composition comprising such a polymer-lipid hybrid nanoparticle and uses of such a polymer-lipid hybrid nanoparticle and/or composition as a vaccine, a pharmaceutical, means of targeting cells, tissues and/or organs and/or non-viral delivery system capable of delivering nucleotides to inside a cell.
Resumen de: US2025235531A1
The present disclosure provides compositions and methods for the preparation, manufacture, and therapeutic use of lipid nanoparticles comprising nucleic acid vaccines, e.g., mRNA vaccines, for delivery to mucosal surfaces.
Resumen de: US2025235551A1
Porous microcarriers prepared from a poly(lactide-co-glycolide) and a porogen, which are suitable for loading of therapeutic lipid nanoparticles into the pores thereof.
Resumen de: US2025235525A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Resumen de: AU2023410864A1
The invention provides a composition, e.g., in the form of a powder, comprising chitosan particles. The invention also provides method for treating an oral condition in a patient by administering to the patient a composition of the invention to treat the oral condition. The invention further provides devices suitable for administering the composition.
Nº publicación: AU2024207086A1 24/07/2025
Solicitante:
NORTHMIRS INC
UNITY HEALTH TORONTO
NORTHMIRS, INC,
UNITY HEALTH TORONTO
Resumen de: AU2024207086A1
A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.
BOPI
Sede Electrónica
